TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Brief Summary: The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent chemotherapy.


Options:
A: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise
B: Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training, Other: Placebo comparator: standard physiotherapy | Arm Label: Standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo comparator: standard physiotherapy | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training | Intervention Type: OTHER; Name: Placebo comparator: standard physiotherapy; Assigned to Arm(s): Inspiratory muscle training, Standard physiotherapy
C: Arm Label: Resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Resistance training
D: Arm Label: Control - usual care; Type: OTHER; Interventions: Other: Usual care | Arm Label: Exercise + usual care; Type: OTHER; Interventions: Other: Usual care, Other: Exercise | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control - usual care, Exercise + usual care | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise + usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Brief Summary: The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent chemotherapy.


Options:
A: Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training, Other: Placebo comparator: standard physiotherapy | Arm Label: Standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo comparator: standard physiotherapy | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training | Intervention Type: OTHER; Name: Placebo comparator: standard physiotherapy; Assigned to Arm(s): Inspiratory muscle training, Standard physiotherapy
B: Arm Label: PLEACE 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anterolateral thoracotomy, Procedure: Posterolateral thoracotomy | Arm Label: PLEACE 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: VATS, Procedure: Anterolateral Thoracotomy | Intervention Type: PROCEDURE; Name: Anterolateral thoracotomy; Assigned to Arm(s): PLEACE 1 | Intervention Type: PROCEDURE; Name: Posterolateral thoracotomy; Assigned to Arm(s): PLEACE 1 | Intervention Type: PROCEDURE; Name: VATS; Assigned to Arm(s): PLEACE 2 | Intervention Type: PROCEDURE; Name: Anterolateral Thoracotomy; Assigned to Arm(s): PLEACE 2
C: Arm Label: Physical training; Type: OTHER; Interventions: Other: Physical training | Arm Label: As usual; Type: OTHER; Interventions: Other: As usual | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training | Intervention Type: OTHER; Name: As usual; Assigned to Arm(s): As usual
D: Arm Label: Resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Resistance training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient and Provider Interventions for Managing Osteoarthritis in Primary Care
Brief Summary: Osteoarthritis (OA) is one of the most common chronic conditions and a leading cause of disability among veterans. Many veterans with OA have significant pain and functional limitations, even though they receive some medical care for their OA. Efforts are needed to help veterans to improve OA-related outcomes. This study will examine a comprehensive approach to helping veterans manage their OA-related symptoms, in the context of a VA clinical setting. The study examines an intervention aimed at helping veterans with behaviors that are known to improve OA-related pain and function (such as exercise, weight management, and coping with pain), as well as helping providers to implement evidence-based recommendations for clinical care. The intervention is relatively low cost and easy to disseminate, with the patient component being telephone based. Therefore, if effective, this intervention could be implemented widely across the VA healthcare system.


Options:
A: Intervention Type: BEHAVIORAL; Name: self-management program; Assigned to Arm(s): N/A
B: Arm Label: Patient education; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Patient education and supervised exercise | Arm Label: Patient education and supervised exercise; Type: EXPERIMENTAL; Interventions: Procedure: Patient education and supervised exercise | Intervention Type: PROCEDURE; Name: Patient education and supervised exercise; Assigned to Arm(s): Patient education, Patient education and supervised exercise
C: Arm Label: Patient education programme; Type: EXPERIMENTAL; Interventions: Other: Patient education programme | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient education programme; Assigned to Arm(s): Patient education programme
D: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Intervention; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response Curve - Sacral Nerve Stimulation for Faecal Incontinence
Brief Summary: The purpose of this study is to determine if subsensory stimulation (amplitude) will maintain same continence in patients treated with Sacral Nerve Stimulation (SNS) for faecal incontinence as stimulation with amplitude at sensory threshold.


Options:
A: Arm Label: InterStim therapy; Type: EXPERIMENTAL; Interventions: Device: Type: Implantable neurostimulator; InterStim | Intervention Type: DEVICE; Name: Type: Implantable neurostimulator; InterStim; Assigned to Arm(s): InterStim therapy
B: Arm Label: Blinded injection of NASHA/Dx gel at randomization.; Type: EXPERIMENTAL; Interventions: Device: NASHA/Dx (Solesta) Gel | Arm Label: Blinded sham inject. at randomization; Type: SHAM_COMPARATOR; Interventions: Device: Sham Injection | Arm Label: Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.; Type: OTHER; Interventions: Device: NASHA/Dx (Solesta) Gel, Device: Sham Injection | Intervention Type: DEVICE; Name: NASHA/Dx (Solesta) Gel; Assigned to Arm(s): Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo., Blinded injection of NASHA/Dx gel at randomization. | Intervention Type: DEVICE; Name: Sham Injection; Assigned to Arm(s): Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo., Blinded sham inject. at randomization
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2
D: Arm Label: Sensory threshold - Amplitude; Type: ACTIVE_COMPARATOR; Interventions: Device: Sensory Threshold | Arm Label: 25% below sensory threshold - Amplitude; Type: EXPERIMENTAL; Interventions: Device: 75% of sensory threshold - Amplitude | Arm Label: 50% below sensory threshold - Amplitude; Type: EXPERIMENTAL; Interventions: Device: 50% of sensory threshold - Amplitude | Intervention Type: DEVICE; Name: Sensory Threshold; Assigned to Arm(s): Sensory threshold - Amplitude | Intervention Type: DEVICE; Name: 75% of sensory threshold - Amplitude; Assigned to Arm(s): 25% below sensory threshold - Amplitude | Intervention Type: DEVICE; Name: 50% of sensory threshold - Amplitude; Assigned to Arm(s): 50% below sensory threshold - Amplitude

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo
Brief Summary: This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.


Options:
A: Arm Label: AXS-05; Type: EXPERIMENTAL; Interventions: Drug: AXS-05 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AXS-05; Assigned to Arm(s): AXS-05 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Placebo then MK-0657; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Arm Label: MK-0657 then Placebo; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Intervention Type: DRUG; Name: MK-0657; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657
D: Arm Label: AZD6765 75 mg; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: AZD6765 150 mg; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Ketamine 0.5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: 125 mL sterile NaCl 0.9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 75 mg | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 150 mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.5 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 125 mL sterile NaCl 0.9%

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit
Brief Summary: The investigators hypothesized that an enriched focus on mother-infant bonding during a newborn's hospitalization in the Neonatal Intensive Care Unit would reduced the rate maternal postpartum smoking relapse and would prolong the duration of breastfeeding in mothers who had quit smoking during or just prior to pregnancy.


Options:
A: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline Service + 10 automated monitoring calls | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Quitline service + 20 automated monitoring calls | Intervention Type: BEHAVIORAL; Name: Quitline Service + 10 automated monitoring calls; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Quitline service + 20 automated monitoring calls; Assigned to Arm(s): Group C
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
C: Intervention Type: BEHAVIORAL; Name: Smoking Relapse Prevention; Assigned to Arm(s): N/A
D: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SBIRT in New Mexico
Brief Summary: The purpose of this study is to compare the effectiveness in reducing drug use and its associated problems of a brief intervention for drug use delivered by a behavioral health counselor as compared to a brief intervention delivered by a computerized intervention.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention using motivational interviewing | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief intervention using motivational interviewing; Assigned to Arm(s): 1
B: Arm Label: CapOpus; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavioral therapy with motivational interviewing, Behavioral: Non-manualized standard treatment | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-manualized standard treatment | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy with motivational interviewing; Assigned to Arm(s): CapOpus | Intervention Type: BEHAVIORAL; Name: Non-manualized standard treatment; Assigned to Arm(s): CapOpus, Treatment as usual
C: Intervention Type: BEHAVIORAL; Name: Motivational Interview with care plan and education; Assigned to Arm(s): N/A
D: Arm Label: Computerized Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Computerized brief intervention | Arm Label: Counselor delivered brief intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselor delivered brief intervention | Intervention Type: BEHAVIORAL; Name: Computerized brief intervention; Assigned to Arm(s): Computerized Brief Intervention | Intervention Type: BEHAVIORAL; Name: Counselor delivered brief intervention; Assigned to Arm(s): Counselor delivered brief intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
Brief Summary: The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.


Options:
A: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tight glucose control; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Arm Label: Standard glucose control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Asp(B28)- | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight glucose control | Intervention Type: DRUG; Name: Insulin, Asp(B28)-; Assigned to Arm(s): Standard glucose control
D: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
Brief Summary: The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.


Options:
A: Arm Label: linagliptin 5mg; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin 5mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Linagliptin 5mg; Assigned to Arm(s): linagliptin 5mg
B: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Glukose-infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-infusion | Arm Label: Glucose-insulin infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-insulin infusion | Intervention Type: DRUG; Name: Glucose-infusion; Assigned to Arm(s): Glukose-infusion | Intervention Type: DRUG; Name: Glucose-insulin infusion; Assigned to Arm(s): Glucose-insulin infusion
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
D: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
Brief Summary: The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.


Options:
A: Arm Label: Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glipizide | Arm Label: glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): glipizide
C: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
D: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 100 mg, Drug: Antihyperglycemic agent(s) | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300 mg, Drug: Antihyperglycemic agent(s) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antihyperglycemic agent(s), Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin 100 mg; Assigned to Arm(s): Canagliflozin 100 mg | Intervention Type: DRUG; Name: Canagliflozin 300 mg; Assigned to Arm(s): Canagliflozin 300 mg | Intervention Type: DRUG; Name: Antihyperglycemic agent(s); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C